Securities code: 002294 securities abbreviation: Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) No.: 2022-003
Shenzhen Salubris Pharmaceuticals Co.Ltd(002294)
Announcement on change of financial principal
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without falsehood
False records, misleading statements or material omissions.
Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) (hereinafter referred to as “the company”) recently received a written resignation report submitted by Ms. Liu Jun, the financial director of the company. Ms. Liu Jun officially retired from the company due to her age and applied to resign as the financial director of the company. After the resignation takes effect, he will no longer hold any position in the company.
According to the guidelines for the standardized operation of listed companies of Shenzhen Stock Exchange and the articles of association, Ms. Liu Jun’s resignation report shall take effect when it is delivered to the board of directors. Ms. Liu Jun’s resignation will not affect the normal operation of relevant work of the company.
As of the disclosure date of this announcement, Ms. Liu Jun has no commitments that should be fulfilled but not fulfilled. At present, it directly holds 84806 shares of the company and indirectly holds 300000 shares of the company through the employee stock ownership plan. After leaving office, Ms. Liu Jun will continue to comply with the company law of the people’s Republic of China, the guidelines for the standardized operation of listed companies of Shenzhen Stock Exchange, the detailed rules for the implementation of share reduction by shareholders, directors, supervisors and senior managers of listed companies of Shenzhen Stock Exchange and other relevant laws and regulations, as well as the measures for the management of employee stock ownership plans. The company will handle relevant share locking matters at the clearing company within 2 trading days after his declaration of resignation.
During her tenure, Ms. Liu Jun was diligent and conscientious. The company sincerely thanks Ms. Liu Jun for her contributions during her tenure!
Upon nomination by the general manager and review by the nomination committee of the board of directors, the company held the 24th Meeting of the 5th board of directors on December 30, 2021. With 9 people agreeing, 0 opposing and 0 abstaining, the proposal on appointing Ms. Kong Yun as the financial director was reviewed and approved, and Ms. Kong Yun was agreed to be appointed as the financial director. The term of office was the same as that of the 5th board of directors, It shall take effect from the date of deliberation and approval by the board of directors. At the same time, it is agreed that the financial director of the company shall receive salary according to the company’s salary regulations according to his specific management positions in the company. (attached with resume) in the 5th board of directors of the company, the total number of directors concurrently holding senior management positions did not exceed 1 / 2 of the total number of directors of the company. The board of directors does not have a director held by an employee representative.
The independent directors express the following independent opinions on the proposal of appointing the financial director:
After reviewing Ms. Kong Yun’s resume and other materials, it is not found that she is not allowed to serve as a senior manager of the company as stipulated in Article 146 of the company law and article 3.2.3 of the guidelines for the standardized operation of listed companies of Shenzhen Stock Exchange, nor is she confirmed as a market prohibited person by the CSRC and the prohibition has not been lifted; He / she meets the qualifications and qualifications of senior managers as stipulated in the company law and the articles of association, and is competent for the duties of the post he / she is employed. The nomination and appointment procedures of the board of directors comply with the company law, the articles of association and other relevant provisions, and are legal and effective. We agree to appoint Ms. Kong Yun as the financial director. At the same time, it is agreed that the financial director of the company shall receive salary according to the company’s salary regulations according to his specific management positions in the company.
It is hereby announced
Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) board of directors
January 4, 2002
Attachment: Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) resume of financial director
Attached:
Shenzhen Salubris Pharmaceuticals Co.Ltd(002294)
Resume of financial director
Kong Yun, Chinese nationality, without overseas residency, female, born in March 1973, bachelor degree, Chinese certified public accountant (non practicing).
After graduation, he successively worked in Shenzhen International Enterprise Co., Ltd., Ricoh Electronic Technology (China) Co., Ltd. Shenzhen Branch, Shenzhen Yisheng Auction Co., Ltd. and Wal Mart (China) Investment Co., Ltd. He has worked in Shenzhen Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) Pharmaceutical Co., Ltd. since December 2006 as the manager of planning and finance department, served as the chief financial officer of Shenzhen Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) Pharmaceutical Co., Ltd. from June 2010 to April 2016, and worked in Shenzhen Zhongdao Asset Management Co., Ltd. from May 2016 to September 2021. From October 2021 to now, he has worked in the Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) financial center.
Ms. Kong Yun does not hold the company’s shares and has no relationship with the shareholders, actual controllers, directors, supervisors and other senior managers who hold more than 5% of the company’s shares; There are no circumstances specified in Article 146 of the company law, no circumstances listed in article 3.2.3 of the guidelines for the standardized operation of listed companies of Shenzhen Stock Exchange, no punishment from CSRC and other relevant departments, no investigation or investigation, and no punishment from the stock exchange, It is not publicized by the CSRC on the public inquiry platform of illegal and dishonest information in the securities and futures market, and it is not a dishonest person after inquiry on the website of the Supreme People’s court; The qualification meets the company law, the Listing Rules of Shenzhen Stock Exchange, other rules of Shenzhen Stock Exchange and the articles of association.
